EGM Result and C Share Issue

Intl. Biotechnology Trust PLC
07 February 2007


                                                                                                                        
                                                                 7 February 2007



             Extraordinary General Meeting and Issue of C Shares


The Board of Directors of International Biotechnology Trust plc (the 'Company')
is pleased to announce that at the Extraordinary General Meeting of the Company
held on Wednesday, 7 February 2007 at 31 Gresham Street, London EC2V 7QA at 3.00
p.m., the  resolution set out in the Notice of Meeting relating to, inter alia,
the issue of C Shares (the 'Issue') by way of a placing and offer for
subscription and also authorisation for the Company to make market purchases of
its Ordinary Shares and C Shares, was duly passed.

A total of 21,513,583 C shares have been allotted pursuant to the Placing and
3,263,850 C Shares have been allotted pursuant to the Offer for Subscription,
giving an aggregate of 24,777,433 C Shares allotted pursuant to the Issue. Such
allotment is conditional on admission to the Official List of the UK Listing
Authority and commencement of dealings in the C Shares on the London Stock
Exchange, which is expected to take place on 12 February 2007. The initial net
asset value of the C Shares is estimated at 145.8 pence per C Share.

The net proceeds of the Issue and the investments made with them will be
accounted for, and managed as, a separate pool of assets until immediately
preceding the earlier of the date on which 85 per cent. of the net proceeds have
been invested and the date falling six months after the date of admission to the
Official list and to trading on the London Stock Exchange. Conversion of the C
Shares into Ordinary Shares in the Company will take place shortly thereafter.

Commenting on the Issue, Andrew Barker, Chairman of the Company, said, 'We are
delighted to have increased the capital base of the Company and broadened the
investor base. Conversion of the C Shares is also expected to increase the
Company's market capitalisation to in excess of £100 million, thus meeting a key
objective of the Issue. The success of the Issue demonstrates investor support
for the specialist mandate of the Company and the strong credentials of the
Company's investment manager, SV Life Sciences.'



Enquiries:


SV Life Sciences Managers LLP
Kate Bingham/Andy Smith                                       020 7421 7070


Cenkos Securities plc
William Rogers/Charlie Ricketts/Paul Palmer                   020 7397 8900


Smith's Corporate Advisory
Hugh Van Cutsem/Christopher Getley                            020 7239 0144


International Biotechnology Trust plc
Andrew Barker                                                 020 7658 3206


Lansons Communications
Amy Fisher/Henrietta Guthrie                                  020 7294 3612





                      This information is provided by RNS
            The company news service from the London Stock Exchange                  GQM